Clinique Saint Hilaire

Rouen 9 trials 3 recruiting

9 Registered trials

3 Currently recruiting

Organisation

Clinique Saint Hilaire

Location

Rouen, France

Identifier

ORG-100046690

Address

2 Place Saint Hilaire, 76000, France

Departments

2411: Cardiology
Cardiologie
CARDIOLOGIE INTERVENTIONNELLE
Cardiology
CICV
ONCOLOGY

Clinical trials at this site (9)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneou… Recruiting

2023-507545-28-00 Elderly patients ≥ 65 years successfully treated with p 6 2026-03-06
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Antiplatelet therapy after successful percutaneous coronary intervention for chronically occluded coronary artery: A prospective, multicentr… Recruiting

2023-508148-23-01 chronically occluded coronary artery 5 2024-12-02
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanc… Ended

2024-515533-15-00 Locally advanced cervical cancer 4